Good morning everyone,
I have received notice of another German investor, who recently received a reply from Todd and he allowed me to share the contend of Todd's email with you (he is a silent reader to this forum, too). I think this response has a little more meat on the bones, which is why I want to share it with you (this email is from last Friday, April 3rd):
Hello XXX,
I hope you are well.
I have only had an email relationship with you since the beginning of Nov, so I can only assume you became a shareholder around that time.
Don’t get me wrong whether you have been a shareholder of 1 week or ten years, or whether you own 10 shares or 1 million shares you are going to be treated with the same respect.
That said, for the sake of history since Jan 2017 when Joe Moscato took over Generex Biotechnology Corp. & brought back from more or less being a dead corporation. To where today, 3 years later investors from that point are doing well.
Don’t get mad about that statement because yes, that is water under the bridge but…
From then to now that comprises of an original 1000 -1 rollback (Mach 2017) because, the company for lack of a better term was broken, and 2 GNBT shareholder dividends since then.
1 share got you 20 shares Dec 3rd, 2018
& 5 shares got you 2 additional shares Feb 2020.
I also add in the 2 sets of shares dividends of NuGenerex Immuno-Oncology / Formally Antigen Express - (not yet a publicly trading company)
All the corporate acquisitions and all the debt that had to be managed and accounted for, to get us to where we are today.
For you own understanding, this has been a monumental task that we planed for, but unforeseen storm clouds hit all startup corporations and we were not immune.
We work to get Generex Biotechnology Corp. back to the Nasdaq. Then firms, institution and the larger investor base that don’t buy OTC stocks will become interested in what we are doing.
That’s why we go to such lengths to file S-1’s so we can raise institutional money leading us to become Nasdaq compliant.
Why? How? They will buy stock & hold it on their books, and write research reports, and have us as presenters at their Pharma Investment Conferences and that is how to build a company for years, decades of advancing success.
That’s what is being built, this is what Joe Moscato & [his team] has put together.
All Corporate assets under the Generex & NuGenerex Family of Companies make us very undervalued.
& I am never one to say buy, sell, or hold and try never to give dates but I will say that even after a day of selling pressure like the last 15 minutes of trading today, that has no attachment to anything that has happened corporately, we are far from KO'd.
As far as work on COVID-19, since before mid-Jan when the first indications of what was happening with Corvid-19 were starting to emerge to the global community.
The full weight of our company was phoning & knocking on doors (FYI - we know who to reach out to) detailing our corporate abilities.
Theas actions continue today, but until corporate actions and activities are complete we do not, and cannot talk about them.
We have been highlighted in many write-ups as having advanced science in this field.
I point to articles that we are highlighted in over the past weeks, as further evidence of what we are working on & our vaccine platform abilities.
In our Press Releases, we discuss our corporate advancements.
With notable consideration for all corporate activities and regulatory steps moving forward today.
When material events take place, a Press Release will immediately follow.
I would like you to also please keep in mind that action surrounding Covid-19 change by the hour/day & we hope to get news out shortly.
Today’s stock price has no comparability with our companies real value… None, but that’s our stock price today, and we move forward.
We have many actions underway corporately that will add to our worth but I point out to everyone until they are signed off & announced, they are all still a work in progress.
(... I skipped a couple of paragraphs here, which contains only the stuff that can be found on GNBT's website ...)
Our foundation is revenue-based which gives us a firm footing moving forward and the companies foundation i.e. NuGenerex Health: NuGenerex Distribution Solutions:
Furthermore, the expected strong growth in many areas of new products and services offered to the marketplace like NuGenerex Regenerative Medicine: NuGenerex Surgical Products: Olaregen’s Excellagen, to name just one product example will drive the company’s future growth & successes.
All corporate activities to date, as well as the dividends, are a thank you to shareholders & a statement of confidence to the marketplace to look at what Generex Biotechnology Corp. is putting together, and recognize the opportunity it presents. Every day we work to build & grow Generex Biotechnology Corp.
Our President & Chief Executive Officer Joseph Moscato will continue to update shareholder as to pending acquisitions and previously discussed corporate actions.
We will continue to communicate with shareholders our company’s operational progress, strategic plans, and M&A activities as soon as they take place.
If you would like to discuss anything further please don’t hesitate to call me.
1 800 391 6755 x 222
Regards,
Todd
I have received notice of another German investor, who recently received a reply from Todd and he allowed me to share the contend of Todd's email with you (he is a silent reader to this forum, too). I think this response has a little more meat on the bones, which is why I want to share it with you (this email is from last Friday, April 3rd):
Hello XXX,
I hope you are well.
I have only had an email relationship with you since the beginning of Nov, so I can only assume you became a shareholder around that time.
Don’t get me wrong whether you have been a shareholder of 1 week or ten years, or whether you own 10 shares or 1 million shares you are going to be treated with the same respect.
That said, for the sake of history since Jan 2017 when Joe Moscato took over Generex Biotechnology Corp. & brought back from more or less being a dead corporation. To where today, 3 years later investors from that point are doing well.
Don’t get mad about that statement because yes, that is water under the bridge but…
From then to now that comprises of an original 1000 -1 rollback (Mach 2017) because, the company for lack of a better term was broken, and 2 GNBT shareholder dividends since then.
1 share got you 20 shares Dec 3rd, 2018
& 5 shares got you 2 additional shares Feb 2020.
I also add in the 2 sets of shares dividends of NuGenerex Immuno-Oncology / Formally Antigen Express - (not yet a publicly trading company)
All the corporate acquisitions and all the debt that had to be managed and accounted for, to get us to where we are today.
For you own understanding, this has been a monumental task that we planed for, but unforeseen storm clouds hit all startup corporations and we were not immune.
We work to get Generex Biotechnology Corp. back to the Nasdaq. Then firms, institution and the larger investor base that don’t buy OTC stocks will become interested in what we are doing.
That’s why we go to such lengths to file S-1’s so we can raise institutional money leading us to become Nasdaq compliant.
Why? How? They will buy stock & hold it on their books, and write research reports, and have us as presenters at their Pharma Investment Conferences and that is how to build a company for years, decades of advancing success.
That’s what is being built, this is what Joe Moscato & [his team] has put together.
All Corporate assets under the Generex & NuGenerex Family of Companies make us very undervalued.
& I am never one to say buy, sell, or hold and try never to give dates but I will say that even after a day of selling pressure like the last 15 minutes of trading today, that has no attachment to anything that has happened corporately, we are far from KO'd.
As far as work on COVID-19, since before mid-Jan when the first indications of what was happening with Corvid-19 were starting to emerge to the global community.
The full weight of our company was phoning & knocking on doors (FYI - we know who to reach out to) detailing our corporate abilities.
Theas actions continue today, but until corporate actions and activities are complete we do not, and cannot talk about them.
We have been highlighted in many write-ups as having advanced science in this field.
I point to articles that we are highlighted in over the past weeks, as further evidence of what we are working on & our vaccine platform abilities.
In our Press Releases, we discuss our corporate advancements.
With notable consideration for all corporate activities and regulatory steps moving forward today.
When material events take place, a Press Release will immediately follow.
I would like you to also please keep in mind that action surrounding Covid-19 change by the hour/day & we hope to get news out shortly.
Today’s stock price has no comparability with our companies real value… None, but that’s our stock price today, and we move forward.
We have many actions underway corporately that will add to our worth but I point out to everyone until they are signed off & announced, they are all still a work in progress.
(... I skipped a couple of paragraphs here, which contains only the stuff that can be found on GNBT's website ...)
Our foundation is revenue-based which gives us a firm footing moving forward and the companies foundation i.e. NuGenerex Health: NuGenerex Distribution Solutions:
Furthermore, the expected strong growth in many areas of new products and services offered to the marketplace like NuGenerex Regenerative Medicine: NuGenerex Surgical Products: Olaregen’s Excellagen, to name just one product example will drive the company’s future growth & successes.
All corporate activities to date, as well as the dividends, are a thank you to shareholders & a statement of confidence to the marketplace to look at what Generex Biotechnology Corp. is putting together, and recognize the opportunity it presents. Every day we work to build & grow Generex Biotechnology Corp.
Our President & Chief Executive Officer Joseph Moscato will continue to update shareholder as to pending acquisitions and previously discussed corporate actions.
We will continue to communicate with shareholders our company’s operational progress, strategic plans, and M&A activities as soon as they take place.
If you would like to discuss anything further please don’t hesitate to call me.
1 800 391 6755 x 222
Regards,
Todd
3
